Cormorant Asset Management, LP Avrobio, Inc. Transaction History

Cormorant Asset Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$10.54 - $19.3 $2.57 Million - $4.71 Million	-244,032 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$12.99 - $19.41 $955,375 - $1.43 Million	-73,547 Reduced 23.16%	244,032 $3.18 Million
Q4 2019 Feb 14, 2020	SELL	$13.05 - $21.88 $3.27 Million - $5.49 Million	-250,715 Reduced 44.12%	317,579 $6.39 Million
Q3 2019 Nov 14, 2019	BUY	$14.12 - $23.44 $4.14 Million - $6.87 Million	293,294 Added 106.65%	568,294 $8.02 Million
Q2 2019 Aug 14, 2019	SELL	$13.21 - $27.29 $330,250 - $682,250	-25,000 Reduced 8.33%	275,000 $4.47 Million
Q1 2019 May 15, 2019	SELL	$12.46 - $22.05 $13.2 Million - $23.3 Million	-1,057,784 Reduced 77.91%	300,000 $6.62 Million
Q4 2018 Feb 14, 2019	SELL	$15.43 - $32.7 $2.08 Million - $4.41 Million	-135,000 Reduced 9.04%	1,357,784 $22.6 Million
Q3 2018 Nov 14, 2018	SELL	$26.95 - $52.7 $404,223 - $790,447	-14,999 Reduced 0.99%	1,492,784 $77.4 Million
Q2 2018 Aug 14, 2018	BUY	$28.08 - $31.2 $42.3 Million - $47 Million	1,507,783 New	1,507,783 $43.1 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.